Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1988 Aug;58(2):139–143. doi: 10.1038/bjc.1988.180

The logistics of broader pre-clinical evaluation of potential anti-cancer agents with reference to anti-tumour activity and toxicity of mitozolomide.

M C Bibby 1, J A Double 1, I A Wahed 1, N Hirbawi 1, T G Baker 1
PMCID: PMC2246776  PMID: 3166903

Abstract

Anti-tumour responses with CCRG81010, M & B 39565, NSC 353451, 8-carbamoyl-3-(2-chloroethyl)imidazo [5,1-d]-1,2,3,5-tetrazin-4(3H)-one (Mitozolomide) in a panel of 4 murine colon tumours of varying growth characteristics and chemosensitivity and a spontaneous murine lymphoma are similar to those seen with standard nitrosoureas. The moderately well differentiated colon adenocarcinoma MAC 16 is nonresponsive to mitozolomide and methylCCNU. Responses in the other 4 lines studied are only achieved near to maximum tolerated dose and at this level there is severe host toxicity. Haemopoietic toxicity is clearly demonstrated by analysis of peripheral blood counts and by CFU-S assays and severe testicular and ovarian toxicity was also seen at dose levels necessary to achieve anti-tumour effects. Using mitozolomide as an example, the study has demonstrated the feasibility of conducting simple but thorough toxicity evaluation for the determination of the therapeutic index. This approach would provide invaluable guidelines for the selection for clinical trial of the most appropriate members of a series of new cytotoxic compounds.

Full text

PDF
139

Images in this article

142Figure 4
on p.142

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abu-Khalaf N., Double J. A., Baker T. G. The comparative effects of cytotoxic agents on the numbers of oocytes in mice. Arch Toxicol Suppl. 1987;11:152–154. doi: 10.1007/978-3-642-72558-6_22. [DOI] [PubMed] [Google Scholar]
  2. Bibby M. C., Double J. A., Ali S. A., Fearon K. C., Brennan R. A., Tisdale M. J. Characterization of a transplantable adenocarcinoma of the mouse colon producing cachexia in recipient animals. J Natl Cancer Inst. 1987 Mar;78(3):539–546. [PubMed] [Google Scholar]
  3. Corbett T. H., Roberts B. J., Leopold W. R., Peckham J. C., Wilkoff L. J., Griswold D. P., Jr, Schabel F. M., Jr Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of the pancreas in C57BL/6 mice. Cancer Res. 1984 Feb;44(2):717–726. [PubMed] [Google Scholar]
  4. Corbett T. H., Valeriote F. A., Baker L. H. Is the P388 murine tumor no longer adequate as a drug discovery model? Invest New Drugs. 1987;5(1):3–20. doi: 10.1007/BF00217664. [DOI] [PubMed] [Google Scholar]
  5. Cowen D. M., Double J. A., Cowen P. N. Some biological characteristics of transplantable lines of mouse adenocarcinomas of the colon. J Natl Cancer Inst. 1980 Mar;64(3):675–681. [PubMed] [Google Scholar]
  6. Double J. A., Ball C. R. Chemotherapy of transplanted adenocarcinomas of the colon in mice. Cancer Chemother Rep. 1975 Nov-Dec;59(6):1083–1089. [PubMed] [Google Scholar]
  7. Double J. A., Ball C. R., Cowen P. N. Transplantation of adenocarcinomas of the colon in mice. J Natl Cancer Inst. 1975 Jan;54(1):271–275. doi: 10.1093/jnci/54.1.271. [DOI] [PubMed] [Google Scholar]
  8. Gibson N. W., Erickson L. C., Hickman J. A. Effects of the antitumor agent 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d]-1,2,3,5-tetrazin-4(3 H)-one on the DNA of mouse L1210 cells. Cancer Res. 1984 May;44(5):1767–1771. [PubMed] [Google Scholar]
  9. Horgan C. M., Tisdale M. J. Antitumour imidazotetrazines--IV. An investigation into the mechanism of antitumour activity of a novel and potent antitumour agent, mitozolomide (CCRG 81010, M & B 39565; NSC 353451). Biochem Pharmacol. 1984 Jul 15;33(14):2185–2192. doi: 10.1016/0006-2952(84)90652-x. [DOI] [PubMed] [Google Scholar]
  10. Meistrich M. L., Hunter N. R., Suzuki N., Trostle P. K., Withers H. R. Gradual regeneration of mouse testicular stem cells after exposure to ionizing radiation. Radiat Res. 1978 May;74(2):349–362. [PubMed] [Google Scholar]
  11. Muggia F. M. Closing the loop: providing feedback on drug development. Cancer Treat Rep. 1987 Jan;71(1):1–2. [PubMed] [Google Scholar]
  12. Newlands E. S., Blackledge G., Slack J. A., Goddard C., Brindley C. J., Holden L., Stevens M. F. Phase I clinical trial of mitozolomide. Cancer Treat Rep. 1985 Jul-Aug;69(7-8):801–805. [PubMed] [Google Scholar]
  13. Schofield R. Assessment of cytotoxic injury to bone marrow. Br J Cancer Suppl. 1986;7:115–125. [PMC free article] [PubMed] [Google Scholar]
  14. Stevens M. F., Hickman J. A., Stone R., Gibson N. W., Baig G. U., Lunt E., Newton C. G. Antitumor imidazotetrazines. 1. Synthesis and chemistry of 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d]-1,2,3,5-tetrazin-4(3 H)-one , a novel broad-spectrum antitumor agent. J Med Chem. 1984 Feb;27(2):196–201. doi: 10.1021/jm00368a016. [DOI] [PubMed] [Google Scholar]
  15. TILL J. E., McCULLOCH E. A. A direct measurement of the radiation sensitivity of normal mouse bone marrow cells. Radiat Res. 1961 Feb;14:213–222. [PubMed] [Google Scholar]
  16. Wahed I., Bibby M. C., Baker T. G. Quantitative methods for assessing the effects of some anticancer drugs on mouse spermatogenesis. Arch Toxicol Suppl. 1987;11:273–276. doi: 10.1007/978-3-642-72558-6_50. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES